OTC Markets EXMKT - Delayed Quote USD

RespireRx Pharmaceuticals Inc. (RSPI)

0.0023

0.0000

(0.00%)

At close: April 16 at 3:58:51 PM EDT

RespireRx Pharmaceuticals Inc. CFO and CEO Issue Letter to Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Parties

Glen Rock, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, today provides a progress and status report to its stockholders, stakeholders, strategic partners as well as other interested parties. Dear Stockholders, Stakeholders, Strategic and Potential Strategic Partners and Other Interested Partie

GlobeNewswire 2 months ago

RSPI
0.00%
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury

Glen Rock, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Markets: RSPI) (RespireRx or the Company), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is delighted to announce that the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study in order to determine

GlobeNewswire 10 months ago

RSPI
0.00%

Performance Overview

Return	RSPI	S&P 500 (^GSPC)
YTD	+187.50%	-10.18%
1-Year	+155.56%	+5.19%
3-Year	-74.44%	+20.26%